Online inquiry

IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9596MR)

This product GTTS-WQ9596MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VSIR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_022153.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64115
UniProt ID Q9H7M9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9596MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2729MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ13199MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ7570MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ568MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ14951MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ3504MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ46MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ9258MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW